Compare Kaltura Inc (KLTR) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs Eli Lilly And Co — how do they compare? Kaltura Inc trades at $1.32 (market cap $199.08M), while Eli Lilly And Co trades at $1,177.75 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 5224× Kaltura Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and Eli Lilly And Co for 93 Days on average.
| KLTR | LLY | |
|---|---|---|
Market Cap | $199.08M | $1.04T |
Volume | 175,927 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $1.89 | $1.28K |
52-Week Low | $1.08 | $799.57 |
Typical Hold Time | 21 Days | 93 Days |
Enterprise Value | $211.29M | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLTR trades at $1.32, down 0.75% on the day, with bearish technical signals from moving averages. The company shows improving fundamentals with revenue stabilizing around $181M and narrowing losses, though it remains unprofitable with negative ROE. Recent analyst coverage leans positive with 44% buy ratings, supported by multiple industry awards and AI platform deployments in 2026.
The outlook remains speculative given persistent losses and high valuation ratios, but growing AI integration and award recognition provide catalysts. Key risks include cash burn, competitive pressure, and execution challenges in achieving profitability. Wall Street sentiment is cautiously optimistic despite technical weakness.
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
